Time filter

Source Type

Columbus, OH, United States

Rivas-Perez H.,Ohio State University | Nana-Sinkam P.,Ohio State University | Nana-Sinkam P.,201 Davis Heart and Lung Research Institute
Respiratory Medicine | Year: 2015

Introduction Lung cancer is the number one cause of cancer related deaths. It is increasingly recognized that a multidisciplinary approach to the diagnosis and management of patients with lung cancer represents the ideal model for health care delivery. Given the high incidence of comorbid lung disease in lung cancer patients, strategies targeted at improving or optimizing these conditions may improve outcomes. Pulmonary rehabilitation (PR) has proven to be a useful management strategy for patients with chronic lung diseases including chronic obstructive pulmonary disease, interstitial lung disease and pulmonary hypertension. Discussion PR improves both exercise capacity and dyspnea. The effects of PR have also been studied in patients with lung cancer prior to and following surgical resection. Investigators have demonstrated significant improvements in six minute walk distance and lower extremity strength. In addition, patient recovery time is shorter when inpatient pulmonary rehabilitation is integrated prior to or following surgery. There are also positive reports regarding the benefits of exercise training in lung cancer patients receiving definite chemotherapy and radiotherapy. Pilot studies have demonstrated improvement in dyspnea scores as well as exercise capacity objectively measured by six minute walk distance. PR also offers an educational component in which patients have the opportunity to be educated regarding management of their disease as well as discuss goals of care. Conclusion PR can be included as the standard of care for patients with advanced lung cancer with the goal of optimizing quality of life. Here, we provide a review of the current knowledge regarding PR in the management of patients with lung cancer. © 2015 Published by Elsevier Ltd. Source

Voorhees J.L.,Ohio State University | Voorhees J.L.,201 Davis Heart and Lung Research Institute | Rao G.V.,Ohio State University | Gordon T.J.,Ohio State University | Brooks C.L.,Ohio State University
FEBS Letters | Year: 2011

Zinc half sites are present in all human lactogenic hormones: human prolactin (hPRL), growth hormone (hGH), placental lactogens (hPL) and the hPRL receptor (hPRLr). The influence of divalent zinc (Zn2+) as measured by intrinsic fluorescence or FRET in each of these hormones is unique and is affected by the presence of varying stoichiometries of hPRLr. These data show that both Zn2+ and hPRLr binding influence hPRL conformers in an interdependent fashion. Although each of these three lactogenic hormones bind hPRLr and induce a biological response that is sensitive to the presence of increasing concentrations of Zn2+, each hormone is unique in the mechanistic details of this process. © 2011 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved. Source

Discover hidden collaborations